Skip to content
Screener

Discontinued — last reported Q2 '24

Total Revenue at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$12.97B+5.7%
Eli Lilly logo
Eli LillyLLY
$22.97B+47.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$25.31B+6.6%
Amgen logo
AmgenAMGN
$10.05B+9.5%
AbbVie logo
AbbVieABBV
$16.99B+10.2%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$65M+466%

Other financials

Income statement

See full
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.94B+1,017%
Enterprise value$5.89B+1,158%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed August 1, 2024.

Filed
Aug 1, 2024
Fiscal quarter
Q2 FY2024
Calendar quarter
Q2 2024
Accession
0000950170-24-089246

The Company devotes substantially all of its efforts towards obtaining regulatory approval and raising capital necessary to fund its operations and it is subject to a number of risks associated with clinical research and development, including dependence on key individuals, the development of and regulatory approval of commercially viable products, the need to raise adequate additional financing necessary to fund the development and commercialization of its products, and competition from larger companies. The Company has not generated revenue to date and has incurred substantial losses and negative cash flows from operations since its inception. The Company has historically funded its operations through issuances of common and preferred stock.

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Oruka Therapeutics, Inc.'s total revenue?
Oruka Therapeutics, Inc. (ORKA) reported total revenue of $0 in Q2 2024.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Oruka Therapeutics, Inc.'s total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude